CRISPR Therapeutics AG

CRSP Healthcare
$53.35 $-0.34 (-0.63%)
Market Cap: $5.08 B
Gurus Holding
3
Popularity Rank
#2679
% of Shares Held
10.31%
Net Activity (Q3 2025)
-$25.42 M

Guru Ownership Trend

Guru Analysis for CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (CRSP), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q3 2025, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $524.22 M.

Top institutional holders include Catherine Wood and Cliff Asness.

Institutional sentiment is currently Slightly Bearish. This is evidenced by a $25.42 M net outflow during the quarter.

Recent activity highlights Cliff Asness who increased their stake by 31.3%. Conversely, Catherine Wood reduced exposure by 3.9%.

Portfolio Manager % Portfolio Activity Shares Value Report Date
3.78% Reduce -3.9% 9,786,973 $634.29 M Q3 2025
0.00% Add 31.3% 28,372 $1.84 M Q3 2025
0.01% Add 4.3% 10,682 $692,300 Q3 2025

Key Holders

Top 5 by Value

$634.29 M
$1.84 M
$692,300

Top 5 by Conviction

Recent Activity Breakdown (Q3 2025)

+$466,697.19
Total Buy Value
New Buys 0
Additions 2
-$25.89 M
Total Sell Value
Reductions 1
Sold Out 1

Guru Consensus (Q3 2025)

Based on recent activity
Net Sellers
2
Net Buyers
2

FAQs for CRISPR Therapeutics AG (CRSP)

Major holders include Catherine Wood ($634.29 M), Cliff Asness ($1.84 M), Murray Stahl ($692,300). According to the latest reported data, 3 tracked investment managers collectively hold approximately 9.83 M shares.

According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $25.42 M, with 2 managers increasing positions and 2 managers reducing holdings.

During the most recent reporting period, 1 managers trimmed their positions, while 1 fully exited CRSP. The total reported sell value was $25.89 M.

Yes, 0 managers opened new positions in CRSP, and 2 increased their existing holdings. The total reported buy value was $466,697.19.